Welcome to our dedicated page for Lemaitre Vasculr news (Ticker: LMAT), a resource for investors and traders seeking the latest updates and insights on Lemaitre Vasculr stock.
LeMaitre Vascular, Inc. (NASDAQ: LMAT) is a provider of vascular devices, implants, and services for the treatment of peripheral vascular disease, with products developed for use by vascular surgeons. This news page aggregates company announcements, earnings releases, and other disclosures so readers can follow how LeMaitre’s vascular device business evolves over time.
In its regular quarterly updates, LeMaitre reports on net sales, gross margin, operating income, earnings per share, and geographic sales across the Americas, EMEA, and Asia Pacific. These releases often highlight which product categories, such as grafts, shunts, and catheters, are driving growth, and may call out specific products like the Artegraft biologic graft used in AV access and peripheral bypass. The company also discusses organic sales growth, adjusted profitability metrics, and the impact of pricing, volume, and manufacturing efficiencies.
Beyond earnings, LeMaitre issues news about dividends, share repurchase authorizations, and participation in healthcare and investor conferences hosted by firms such as Bank of America Securities, Wells Fargo, Morgan Stanley, and others. These events provide additional context on the company’s strategy, international expansion, and regulatory milestones, including launches of products like Artegraft in new markets.
Investors and observers can use this page to review historical press releases, monitor guidance updates, and see how management characterizes risks and opportunities in the peripheral vascular disease market. For ongoing coverage of LMAT news, this feed offers a centralized view of the company’s public communications and financial reporting.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced its Q3 2020 results with sales reaching $36.4 million, reflecting a 25% increase. Operating income surged 70% to $10.0 million, with a net income of $7.5 million, a 45% rise. The company declared a quarterly dividend of $0.095/share. Growth was driven by acquisitions and recovery in elective surgeries. However, gross margin fell to 62.3% from 69.3% a year prior. Guidance for Q4 anticipates sales between $34.0 million and $38.0 million.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced it will release its third quarter 2020 financial results on October 29, 2020, after market close. A conference call is scheduled for 5:00 PM EDT that day to discuss the financial results and the company's outlook. Interested parties can join the call at 844-239-5284 or access the live webcast through their investor relations website.
LeMaitre Vascular specializes in devices for the treatment of peripheral vascular disease, a condition impacting over 200 million people globally.
LeMaitre Vascular (Nasdaq: LMAT) announced its participation in three investor conferences throughout September 2020. JJ Pellegrino, CFO, will engage in the Barrington Research Virtual Fall Investment Conference on September 9, followed by a presentation at the Cantor Virtual Global Healthcare Conference on September 15 at 4:00 PM EDT. Pellegrino will also present at the Sidoti Virtual Investor Conference on September 23 at 10:45 AM EDT. LeMaitre specializes in devices for treating peripheral vascular disease, impacting over 200 million globally.
LeMaitre Vascular, Inc. (Nasdaq: LMAT) announced participation in two upcoming investor conferences in August 2020. CFO JJ Pellegrino will present at the virtual Canaccord Genuity 40th Annual Growth Conference on August 13 at 8:00 AM EDT. Additionally, President David Roberts will attend the virtual 5th Annual Needham Med Tech & Diagnostics 1×1 Conference on August 17. LeMaitre Vascular specializes in devices and services for peripheral vascular disease, which affects over 200 million people globally, offering a diverse range of vascular devices for surgeons.
LeMaitre Vascular, Inc. (LMAT) reported Q2 2020 results, with sales of $24.9 million, a decline of 16% year-over-year. Operating income fell 18% to $4.9 million, while net income decreased by 24% to $3.5 million, resulting in earnings of $0.17 per diluted share, down 25%. Despite a 20% operating margin, sales declined significantly due to the COVID-19 pandemic, particularly in the Americas and Europe. The company announced a quarterly dividend of $0.095 per share and provided limited Q3 guidance, projecting sales between $30.5 million and $34.5 million.
LeMaitre Vascular, Inc. (Nasdaq: LMAT) will release its second quarter 2020 financial results on July 23, 2020, after market close. A conference call is scheduled for 5:00 PM EDT to discuss results, business highlights, and company outlook. LeMaitre offers devices and services for peripheral vascular disease, which affects over 200 million people globally. The company specializes in developing disposable and implantable vascular devices, targeting vascular surgeons with its diverse product portfolio.
LeMaitre Vascular, Inc. (Nasdaq: LMAT) announced the acquisition of Artegraft, Inc. for $90 million, which includes $72.5 million in cash and potential earnouts of $17.5 million. Artegraft, known for its biologic vascular grafts used primarily in hemodialysis patients, generated $15.6 million in trade sales over the last year. This acquisition is expected to enhance LeMaitre's product offerings and profitability, positioning Artegraft as the largest product line in their sales portfolio. The deal will be funded through cash and a $65 million credit facility.
LeMaitre Vascular, Inc. (Nasdaq: LMAT) announced that CFO JJ Pellegrino will speak at the Jefferies Virtual Healthcare Conference on June 4, 2020, at 2:00 PM EDT. LeMaitre Vascular specializes in developing and marketing devices for peripheral vascular disease, which impacts over 200 million individuals globally. The company offers a range of disposable and implantable vascular devices for use by vascular surgeons. More details can be found on their website at www.lemaitre.com.
LeMaitre Vascular, listed on Nasdaq under the symbol LMAT, will be presented by President David Roberts at the UBS Virtual Global Healthcare Conference on May 20, 2020, at 8:20 AM EDT. The company specializes in developing and marketing devices for peripheral vascular disease, impacting over 200 million people globally. Their extensive product range focuses on disposable and implantable vascular devices tailored for vascular surgeons, enhancing treatment options for patients.